Trienekens, P.H.

patient cyp 2c genotype study cyp 2c genotype sulfonylurea variant allele difference therapy glucose polymorphism cyp 2c polymorphisms prescription level tolbutamide complication sulfonylurea therapy wild-type genotype cyp 2c allele rotterdam anticoagulant fi rst prescription acenocoumarol event cyp 2c carriers cohort rotterdam study change 100 treatment-years carrier diabetes wild-type cyp 2c polymorphism variant genotype phenprocoumon cytochrome analysis measurement treatment effect erasmus mc serum study period number glucose levels period mellitu population-based cohort study population anticoagulant therapy netherland initiation phase enzyme coumarin hazard ratios fi rst measurement fasting metabolism anticoagulation type genotype cyp 2c enzyme cyp 2c alleles glimepiride diabetes mellitus glibenclamide hazard warfarin initiation population-based table treatment-year variant alleles variant allele ratio inr ≥ 6.0 phase pharmacol frequency signi ficant differences